Neoleukin Therapeutics Stock Book Value Per Share
Neoleukin Therapeutics fundamentals help investors to digest information that contributes to Neoleukin Therapeutics' financial success or failures. It also enables traders to predict the movement of Neoleukin Stock. The fundamental analysis module provides a way to measure Neoleukin Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neoleukin Therapeutics stock.
Neoleukin |
Neoleukin Therapeutics Company Book Value Per Share Analysis
Neoleukin Therapeutics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Neoleukin Therapeutics Book Value Per Share | 34.18 X |
Most of Neoleukin Therapeutics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neoleukin Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of Neoleukin Therapeutics is about 34.177 times. This is 2110.41% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The book value per share for all United States stocks is 98.23% higher than that of the company.
Neoleukin Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neoleukin Therapeutics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neoleukin Therapeutics could also be used in its relative valuation, which is a method of valuing Neoleukin Therapeutics by comparing valuation metrics of similar companies.Neoleukin Therapeutics is currently under evaluation in book value per share category among its peers.
Neoleukin Fundamentals
| Return On Equity | -0.38 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | (35.02 M) | |||
| Shares Outstanding | 2.35 M | |||
| Shares Owned By Insiders | 16.46 % | |||
| Shares Owned By Institutions | 45.58 % | |||
| Number Of Shares Shorted | 26.4 K | |||
| Price To Earning | (4.60) X | |||
| Price To Book | 0.44 X | |||
| EBITDA | (56.48 M) | |||
| Net Income | (57.56 M) | |||
| Cash And Equivalents | 116.46 M | |||
| Cash Per Share | 2.73 X | |||
| Total Debt | 12.07 M | |||
| Debt To Equity | 0.11 % | |||
| Current Ratio | 12.78 X | |||
| Book Value Per Share | 34.18 X | |||
| Cash Flow From Operations | (45.61 M) | |||
| Short Ratio | 1.70 X | |||
| Earnings Per Share | (12.28) X | |||
| Price To Earnings To Growth | (0.03) X | |||
| Target Price | 1.5 | |||
| Beta | 1.1 | |||
| Market Capitalization | 8.2 M | |||
| Total Asset | 115.95 M | |||
| Retained Earnings | (451.06 M) | |||
| Working Capital | 88.07 M | |||
| Current Asset | 289 K | |||
| Current Liabilities | 1.02 M | |||
| Z Score | -5.73 | |||
| Net Asset | 115.95 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Neoleukin Stock
If you are still planning to invest in Neoleukin Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neoleukin Therapeutics' history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |